Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease

Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Demetrios Andreopoulos, Antoine Engelen, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Karine Peignaux-Casasnovas, Jihane Boustani, Fernanda G. Herrera, Bradley R. Pieters, Annerie Slot, Amit Bahl, Christopher D. Scrase, David Azria, Jan Jansa, Joe M. O’SullivanAlphonsus C.M. Van Den Bergh, Laurence Collette, A. C.M. Van Den Bergh, C. Carrie, S. Villa, N. Kitsios, Ph Poortmans, M. Bolla, S. Sundar, E. M. Van Der Steen-Banasik, J. Armstrong, P. Maingon, J. F. Bosset, A. Zouhair, F. G. Herrera, B. R. Pieters, A. Slot, K. Hopkins, A. Bahl, R. Ben Yosef, V. Budach, D. Boehmer, C. D. Scrase, L. Renard, D. Azria, S. M. Magrini, B. De Bari, J. Jansa, E. Lartigau, Matuszewska, the EORTC Radiation Oncology Group

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)


PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event-(EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) $ 10 ng/mL or Gleason # 7 and PSA # 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis–free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided a 5 5%. RESULTS At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] 5 0.53; CI, 0.41 to 0.70; P, .001 and HR 5 0.67; CI, 0.49 to 0.90; P 5 .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR 5 0.74; CI, 0.53 to 1.02; P 5 .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR 5 0.74; CI, 0.53 to 1.04; P 5 .082). CONCLUSION Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.

Original languageEnglish
Pages (from-to)3022-3033
Number of pages12
JournalJournal of Clinical Oncology
Issue number27
Publication statusPublished - 20 Sept 2021
Externally publishedYes


Dive into the research topics of 'Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease'. Together they form a unique fingerprint.

Cite this